Departing from the European regulatory framework for medicines following the UK’s exit from the EU would pose a significant risk for both the UK off-patent industry and for patient access to affordable medicines, according to Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association.
Speaking to Generics Bulletin just ahead of the UK’s formal departure from the EU, Smith noted that, for the moment,...





